Buyer landscape
Likely buyers · Biotech in Italy.
Prepared 2026-09-29 with GP Intel · deterministic scoring, published weights: gp-intel.com/methodology/league-tables
How companies like this sold · 81 verified exits: 41% to sponsors, 57% to corporates and platforms, 2% via IPO. Route shift since 2020: sponsors 41% (was 40%), corporates and platforms 56% (was 57%), IPO 2% (was 3%).
The list: 25 Tier 1 · 0 Tier 2 of 120 matched buyers, including 20 geographic expansion candidates without a local platform yet. A first round of the Tier 1 names plus the expansion buyers covers the demonstrated demand.
Financial buyers · 24
Tier 1 · Very High · score 70+
1. Merieux Equity Partners / Vitruvian Partners SponsorVery High81
57 platform investments in Healthcare · 7 deals 2024–26
AUM €1.6B · Mérieux Participations 5 · 2026 vintage · deploying · check €7-50M
3 platform investments since the 2026 vintage · early in deployment vs its usual 8 per fund.
Backed Ona Therapeutics, 2026 · Biotech, Spain
2. Bpifrance Investissement SponsorVery High80
15 platform investments in Healthcare · 38 deals 2024–26
AUM €57.3B · Bpifrance Amorçage Industriel · 2023 vintage · deploying · check €1-8M
Accelerating: 32 deals in the last 2 years vs 6.3/yr before.
Backed Adcendo, 2026 · Biotech, Denmark
3. ArchiMed SponsorVery High80
56 platform investments in Healthcare · 6 in Italy · 18 deals 2024–26
AUM €9.0B · MED Rise · 2024 vintage · deploying · check €8-60M
18 platform investments since the 2024 vintage · largely deployed vs its usual 9 per fund.
Backed ExcellGene, 2025 · Biotech, Switzerland
4. Archimedes Partners SponsorVery High80
53 platform investments in Healthcare · 6 in Italy · 21 deals 2024–26
AUM €9.0B · MED Rise · 2024 vintage · deploying · check €8-60M
18 platform investments since the 2024 vintage · largely deployed vs its usual 9 per fund.
Backed ExcellGene, 2025 · Biotech, Switzerland
5. ARCHIMED and Institut Mérieux SponsorVery High80
54 platform investments in Healthcare · 6 in Italy · 19 deals 2024–26
AUM €9.0B · MED Rise · 2024 vintage · deploying · check €8-60M
18 platform investments since the 2024 vintage · largely deployed vs its usual 9 per fund.
Backed ExcellGene, 2025 · Biotech, Switzerland
6. ArchiMed and Tethys Invest SponsorVery High80
54 platform investments in Healthcare · 6 in Italy · 18 deals 2024–26
AUM €9.0B · MED Rise · 2024 vintage · deploying · check €8-60M
18 platform investments since the 2024 vintage · largely deployed vs its usual 9 per fund.
Backed ExcellGene, 2025 · Biotech, Switzerland
7. Quadrivio Group SponsorVery High79
6 platform investments in Healthcare · 28 in Italy · 14 deals 2024–26
AUM €2.0B · Artificial Intelligence PE Fund · 2025 vintage · deploying
6 platform investments since the 2025 vintage · mid-deployment vs its usual 6 per fund.
Backed Biotec Italia, 2025 · MedTech, Italy
8. Audacia SponsorVery High78
9 platform investments in Healthcare · 1 in Italy · 27 deals 2024–26
AUM €2.8B · Audacia Capital Développement IV · 2023 vintage · deploying · check €4-30M
45 platform investments since the 2023 vintage · largely deployed vs its usual 12 per fund.
Backed Biomemory, 2025 · Biotech, France
9. PAI Partners SponsorVery High77
24 platform investments in Healthcare · 16 in Italy · 26 deals 2024–26
AUM €33.0B · PAI Mid-Market Fund II · 2025 vintage · deploying
12 platform investments since the 2025 vintage · largely deployed vs its usual 10 per fund.
Bought Nuzoa from Abac Capital, 2025 · Pharma, Spain
10. Ring Capital SponsorVery High77
10 platform investments in Healthcare · 1 in Italy · 32 deals 2024–26
AUM €470M · Ring Altitude II · 2025 vintage · deploying · check €4-33M
17 platform investments since the 2025 vintage · largely deployed vs its usual 13 per fund.
Backed Exapto, 2024 · Biotech, France
12. Turenne Groupe SponsorVery High76
55 platform investments in Healthcare · 1 in Italy · 34 deals 2024–26
AUM €2.0B · Capital Sante 3 · 2025 vintage · deploying · check €3-21M
20 platform investments since the 2025 vintage · early in deployment vs its usual 80 per fund.
Backed Mablink, 2021 · Biotech, France
13. Novo Holdings SponsorVery High76
114 platform investments in Healthcare · 43 deals 2024–26
AUM €93.0B · Novo Holdings Bioindustrial Investments · 1999 vintage · no newer fund
142 platform investments since the 1999 vintage · largely deployed vs its usual 24 per fund.
Backed cAMPfield, 2026 · Biotech, US
14. NORD Holding SponsorVery High76
15 platform investments in Healthcare · 15 deals 2024–26
AUM €5.0B · NORD Holding all inclusive Fitness Continuation Fund · 2026 vintage · deploying
Accelerating: 13 deals in the last 2 years vs 2.5/yr before.
Bought Hallmarq Veterinary Imaging from August Equity, 2026 · MedTech, UK
15. Lauxera Capital Partners SponsorVery High76
16 platform investments in Healthcare · 6 deals 2024–26
AUM €780M · Lauxera Growth II · 2025 vintage · deploying · check €10-78M
3 platform investments since the 2025 vintage · early in deployment vs its usual 8 per fund.
Backed GenePlanet, 2026 · Biotech, Slovenia
16. Ardian, Finint Infrastrutture SponsorVery High75
64 platform investments in Healthcare · 48 in Italy · 44 deals 2024–26
AUM €196.0B · Ardian Expansion Fund VI · 2025 vintage · deploying · check €64-480M
14 platform investments since the 2025 vintage · mid-deployment vs its usual 15 per fund.
Backed Ourvita + HBI, 2025 · Healthcare, France
17. Inflexion SponsorVery High75
10 platform investments in Healthcare · 27 deals 2024–26
AUM €11.0B · Inflexion Buyout Fund VII · 2026 vintage · deploying · check €90-675M
4 platform investments since the 2026 vintage · mid-deployment vs its usual 6 per fund.
Bought Primed from Paragon Partners, 2026 · MedTech, Germany
18. NORD Holding / Pinova Capital SponsorVery High75
12 platform investments in Healthcare · 12 deals 2024–26
AUM €5.0B · NORD Holding all inclusive Fitness Continuation Fund · 2026 vintage · deploying
Accelerating: 10 deals in the last 2 years vs 2.5/yr before.
Backed Hallmarq Veterinary Imaging, 2026 · MedTech, UK
19. Bridgepoint SponsorVery High74
34 platform investments in Healthcare · 2 in Italy · 43 deals 2024–26
AUM €86.6B · Europe VIII (BE VIII) · 2026 vintage · deploying · check €120-900M
4 platform investments since the 2026 vintage · early in deployment vs its usual 20 per fund.
Bought {my}dentist (formerly IDH) from Palamon Capital Partners, 2025 · Healthcare, UK
20. Idia SponsorVery High74
12 platform investments in Healthcare · 1 in Italy · 30 deals 2024–26
AUM €2.4B · Crédit Agricole Assurances Avenir et Territoires · 2026 vintage · deploying · check €2-15M
8 platform investments since the 2026 vintage · early in deployment vs its usual 26 per fund.
Backed Lagarrigue, 2026 · Healthcare, France
21. Inflexion (Partnership Capital III) SponsorVery High74
9 platform investments in Healthcare · 25 deals 2024–26
AUM €11.0B · Inflexion Buyout Fund VII · 2026 vintage · deploying · check €90-675M
Accelerating: 15 deals in the last 2 years vs 5.0/yr before.
Backed Primed, 2026 · MedTech, Germany
22. Charterhouse Capital Partners SponsorVery High74
11 platform investments in Healthcare · 4 in Italy · 10 deals 2024–26
AUM €7.0B · Charterhouse Capital Partners XI · 2023 vintage · deploying · check €28-210M
10 platform investments since the 2023 vintage · mid-deployment vs its usual 14 per fund.
Backed Animalcare Group, 2026 · Healthcare, UK
23. UI Investissement SponsorVery High74
17 platform investments in Healthcare · 13 deals 2024–26
AUM €1.7B · Cap Autrement · 2023 vintage · deploying
17 platform investments since the 2023 vintage · largely deployed vs its usual 14 per fund.
Backed Brenus Pharma, 2024 · Biotech, France
24. UI Investissement + Bpifrance SponsorVery High74
17 platform investments in Healthcare · 13 deals 2024–26
AUM €1.7B · Cap Autrement · 2023 vintage · deploying
17 platform investments since the 2023 vintage · largely deployed vs its usual 14 per fund.
Backed Brenus Pharma, 2024 · Biotech, France
25. UI Investissement + GENEO Capital Entrepreneur + Management SponsorVery High74
17 platform investments in Healthcare · 13 deals 2024–26
AUM €1.7B · Cap Autrement · 2023 vintage · deploying
17 platform investments since the 2023 vintage · largely deployed vs its usual 14 per fund.
Backed Brenus Pharma, 2024 · Biotech, France
Strategic buyers · 1
Tier 1 · Very High · score 70+
11. Gilead Sciences CorporateVery High77
6 acquisitions in Healthcare · 4 deals 2024–26
Accelerating: 4 deals in the last 2 years vs 0.3/yr before.
Bought Tubulis from Athos, 2026 · Biotech, Germany
Scores and facts derive from verified deal records only; sample floors and thresholds are published on the methodology page. Figures marked with a tilde are bands, not disclosures.